Patients who are obese or overweight are frequently seen in cardiology for other conditions and weight reduction with GLP-1 RAs can be a useful tool in the cardiologist’s toolbox. Through this program, cardiologists will become more familiar with the data supporting the use of GLP 1 RAs in their patients, identify appropriate patients and potential barriers to adherence, and learn how they can more effectively utilize these therapies in their unique patient population.

CME/CE Accreditation Information

Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.

CME/CE Accreditation Information

Patients who are obese or overweight are more likely to require joint replacement surgery than their normal weight peers; however, higher BMIs also substantially increase the risks of orthopedic surgery. This increased risk often leads to orthopedic surgeons requiring that their patients lose weight and obtain a BMI of <40 kg/m2 before proceeding with surgery. In previous years, bariatric surgery may have been the only feasible option for these patients, but now anti-obesity medications, like GLP-1 receptor agonists, are a valid alternative and may be more palatable for patients. Through this program, orthopedic surgeons will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs and enhance their understanding of strategies which can improve patient access and adherence.

CME/CE Accreditation Information

This curriculum was designed in consideration of the critical need to address several long-standing challenges sleep medicine specialists face when treating patients with narcolepsy. A major hurdle has been rapid and accurate diagnosis, given that symptoms often overlap with psychiatric and other neurological conditions. Treatment is also changing; while the treatment landscape has long been dominated by symptomatic management, recent updates to clinical guidelines and the development of mechanism-based therapies, such as OX2R agonists, signal a potential shift in future treatments. After decades of limited therapeutic innovation, narcolepsy is entering a new era of targeted approaches that address underlying pathophysiology. Sleep specialists will likely face new challenges incorporating these investigational therapies into practice once they are available. Offering clinicians a structured opportunity to review emerging data, share practical insights, and discuss implementation strategies represents a timely and impactful opportunity to advance narcolepsy care. However, addressing these complex issues realistically requires a great deal more than participating in a single live or digital educational activity. This program opts for extended interactions, mentoring, and peer-to-peer discussions among small groups of highly qualified and motivated practitioners.

CME/CE Accreditation Information

Postpartum depression (PPD) affects up to one in seven women and is a leading cause of maternal morbidity, with profound implications for both the patient and her family. Untreated PPD can lead to chronic depression, impaired maternal-infant bonding, strained partner relationships, and long-term developmental challenges for the child. These effects are magnified when symptoms go unrecognized or untreated. Early and routine screening, integrated into obstetric and pediatric care, is essential to identify women at risk and initiate timely intervention. Collaborative care models where primary care or OB providers partner with behavioral health care managers and consulting psychiatrists offer a scalable, evidence-based approach to managing PPD. These models improve access to treatment, ensure close follow-up, and have demonstrated superior outcomes compared to standard care.

CME/CE Accreditation Information

Welcome to this curriculum on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This program is designed to provide you with the latest strategies for accurately diagnosing, staging, and treating GEP-NETs by integrating pathological grading with advanced imaging and novel systemic therapies. This activity emphasizes a collaborative approach, encouraging multidisciplinary care coordination to personalize treatment plans and optimize outcomes for patients with this complex disease.

CME/CE Accreditation Information

This curriculum provides practical guidance on the diagnosis and management of eosinophilic esophagitis (EoE), a chronic, immune-mediated disease of the esophagus with rising prevalence. Learners will engage with current diagnostic algorithms, examine treatment options including dietary therapy, topical corticosteroids, and biologics, and explore strategies to meet payer documentation requirements for timely access to care. Designed for gastroenterologists, allergists, and other clinicians involved in the care of patients with EoE, the program emphasizes accurate diagnosis, coordinated multidisciplinary care, and personalized, evidence-based treatment planning.

CME/CE Accreditation Information

Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.

CME/CE Accreditation Information

Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies. With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination. This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care. Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.

CME/CE Accreditation Information

This interactive program equips neurology providers with practical strategies to improve care for patients with myasthenia gravis. Grounded in real-world clinical challenges, the content focuses on early identification of high-risk patients, individualized treatment planning, and effective integration of newly approved and emerging therapies. Participants will gain insights that can be immediately applied to enhance outcomes across the spectrum of myasthenia gravis severity.

CME/CE Accreditation Information